GeneReach Biotechnology Cash Flow Reinvestment Rate
GeneReach Biotechnology cash flow reinvestment rate. GeneReach Biotechnology (4171) has a Cash Flow Reinvestment Rate of 5.12x as of June 2026, reinvesting NT$32.19 Million (capex NT$8.13 Million plus investments NT$24.06 Million) from operating cash flow of NT$6.28 Million. Explore 4171 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of GeneReach Biotechnology (2018–2022)
Cash flow reinvestment rate of GeneReach Biotechnology from 2018 to 2022. Historical reinvestment intensity for GeneReach Biotechnology across 4 annual periods. Explore capital reinvestment ratio of GeneReach Biotechnology to see what proportion of operating cash flow is directed to capital expenditures.
GeneReach Biotechnology Cash Flow Reinvestment Rate by Year (2018–2022)
GeneReach Biotechnology cash flow reinvestment rate by year from 2018 to 2022. Year-by-year capital reinvestment analysis for GeneReach Biotechnology. For the full cash flow conversion analysis, see GeneReach Biotechnology (4171) cash conversion ratio.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.26x | NT$92.92 Million | NT$357.63 Million | NT$44.90 Million | ▲ +361.7% |
| 2021 | 0.06x | NT$19.64 Million | NT$348.99 Million | NT$15.79 Million | ▼ -86.1% |
| 2020 | 0.40x | NT$68.72 Million | NT$169.82 Million | NT$64.87 Million | ▼ -62.3% |
| 2018 | 1.07x | NT$6.16 Million | NT$5.74 Million | NT$2.31 Million | — |